Randomized Phase 3 Trial Evaluating the Efficacy of Locoregional Treatment With Transarterial Embolization (TAE) for Liver Metastases, in Combination With Octreotide LAR, in Patients With Neuroendocrine Tumor and Inoperable Liver Metastasis.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Octreotide (Primary)
Indications Neuroendocrine tumours
Focus Therapeutic Use
Acronyms LOTUS

Most Recent Events

06 May 2016 Biomarkers information updated
29 Jul 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
21 Jan 2013 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight